BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31553693)

  • 21. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    Laurence V; Pierga JY; Barthier S; Babinet A; Alapetite C; Palangié T; de Pinieux G; Anract P; Pouillart P
    Am J Clin Oncol; 2005 Jun; 28(3):301-9. PubMed ID: 15923805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
    Koch R; Gelderblom H; Haveman L; Brichard B; Jürgens H; Cyprova S; van den Berg H; Hassenpflug W; Raciborska A; Ek T; Baumhoer D; Egerer G; Eich HT; Renard M; Hauser P; Burdach S; Bovee J; Bonar F; Reichardt P; Kruseova J; Hardes J; Kühne T; Kessler T; Collaud S; Bernkopf M; Butterfaß-Bahloul T; Dhooge C; Bauer S; Kiss J; Paulussen M; Hong A; Ranft A; Timmermann B; Rascon J; Vieth V; Kanerva J; Faldum A; Metzler M; Hartmann W; Hjorth L; Bhadri V; Dirksen U
    J Clin Oncol; 2022 Jul; 40(21):2307-2320. PubMed ID: 35427190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.
    Burdach S; van Kaick B; Laws HJ; Ahrens S; Haase R; Körholz D; Pape H; Dunst J; Kahn T; Willers R; Engel B; Dirksen U; Kramm C; Nürnberger W; Heyll A; Ladenstein R; Gadner H; Jürgens H; Go el U
    Ann Oncol; 2000 Nov; 11(11):1451-62. PubMed ID: 11142486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
    Raciborska A; Bilska K; Drabko K; Chaber R; Sobol G; Pogorzała M; Wyrobek E; Połczyńska K; Rogowska E; Rodriguez-Galindo C; Wożniak W
    Pediatr Blood Cancer; 2014 Dec; 61(12):2170-4. PubMed ID: 25163763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
    J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
    Thiel U; Wawer A; von Luettichau I; Bender HU; Blaeschke F; Grunewald TG; Steinborn M; Röper B; Bonig H; Klingebiel T; Bader P; Koscielniak E; Paulussen M; Dirksen U; Juergens H; Kolb HJ; Burdach SE
    Oncotarget; 2016 Oct; 7(43):70959-70968. PubMed ID: 27486822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
    Chin M; Yokoyama R; Sumi M; Okita H; Kawai A; Hosono A; Koga Y; Sano H; Watanabe H; Ozaki T; Mugishima H;
    Pediatr Blood Cancer; 2020 May; 67(5):e28194. PubMed ID: 32077253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and therapeutic factors influencing the clinical outcome of metastatic Ewing sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.
    Umeda K; Miyamura T; Yamada K; Sano H; Hosono A; Sumi M; Okita H; Kamio T; Maeda N; Fujisaki H; Jyoko R; Watanabe A; Hosoya Y; Hasegawa D; Takenaka S; Nakagawa S; Chin M; Ozaki T;
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28844. PubMed ID: 33340261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
    Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience.
    Diaz-Beveridge R; Lorente D; Torres B; Cañete A; Rodrigo E; Bruixola G; Berlanga P; Reche E; Montalar J; Verdeguer A; Aparicio J
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e278-84. PubMed ID: 25929608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.
    Bosma SE; Rueten-Budde AJ; Lancia C; Ranft A; Dirksen U; Krol AD; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Fiocco M
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27943. PubMed ID: 31389188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
    Tanaka K; Matsunobu T; Sakamoto A; Matsuda S; Iwamoto Y
    J Orthop Sci; 2002; 7(4):477-82. PubMed ID: 12181663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
    Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
    J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.